Background
BreastSlinda® Study
Observational study to evaluate the acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®) after 5 cycles of use during breastfeeding. BreastSlinda® Study.
OBSERVATIONAL MULTICENTER, RETROSPECTIVE STUDY
Dear Sir or Madam,
We would like to invite you to participate in a study titled. „Observational study to evaluate the acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®) after 5 cycles of use during breastfeeding. BreastSlinda® Study.”, the primary objective of which is to assess the acceptability of Slinda® in breastfeeding women from 1 to 6 months post-partum.

The study is also expected to aid evaluating the bleeding pattern and the tolerability and safety of the treatment, as well as, investigating the infant outcome.

It is necessary to conclude an online contract in order to start the study, therefore we ask for registering and following the information on the computer screen.

After correct registration and signing the contract in electronic form, please log in data obtained in the process of creating an account.
Project Management
BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
phone: 530 714 118
email: support@biostat.com.pl
Sponsor
Exeltis Polska
ul. Szamocka 8
01-748 Warszawa